Pindolol: No new patients and discontinuation

Discontinuation Access change Active

Pindolol is being discontinued and pindolol will only be funded for existing patients from 1 August 2021.

Why are we doing this? 

All strengths of pindolol (5 mg, 10 mg and 15 mg) are currently supplied by Apotex. Apotex is leaving the New Zealand market. We have been looking for new suppliers for all the medicines they currently supply.

We have been unable to find an alternative supplier for pindolol.

We are making these changes so current patients can access pindolol for as long as possible.

Key dates

1 August 2021: No new patients

  • Funding will be restricted to people who were using pindolol before 1 August 2021.
  • Pharmacists can endorse the script where they have a record of a previous dispensing of pindolol.

1 May 2022: Pindolol delisted

  • We anticipate that stocks of pindolol will be exhausted before the end of the year. The May delisting date allows all stock in the supply chain to be used up. 

Alternative products

We have received clinical advice that other beta-blockers, such as propranolol or metoprolol, may be suitable alternatives for people to be transitioned to.

Beta-adrenoceptor blocking medicines | NZ Formulary(external link)

Beta-adrenoceptor blocking medicines | Pharmaceutical Schedule(external link)

Who to contact 

If you are taking pindolol, talk to your pharmacist or the person who prescribed the pindolol.  They are in the best place to advise on your clinical circumstances.

If you have funding questions about pindolol, email enquiry@pharmac.govt.nz 

Pharmac's response to Apotex's departure